SOLIGENIX INC.NEW DL-,001
SOLIGENIX INC.NEW DL-,001
Aktie · US8342235053 · SNGX · A3D506 (XNCM)
Übersicht Finanzkennzahlen
1,67 EUR
Frankfurt (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
09.06.2025 16:46

Aktuelle Kurse von SOLIGENIX INC.NEW DL-,001

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
SNGX
USD
09.06.2025 16:46
1,91 USD
1,91 USD

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
-0,18 % 0,69 % -4,50 % -23,33 % -43,97 % -52,21 % -99,64 %

Firmenprofil zu SOLIGENIX INC.NEW DL-,001 Aktie

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Unternehmensdaten

Name SOLIGENIX INC.NEW DL-,001
Firma Soligenix, Inc.
Symbol SNGX
Website https://www.soligenix.com
Heimatbörse XNCM Frankfurt
WKN A3D506
ISIN US8342235053
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Christopher J. Schaber Ph.D.
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,0 T
Adresse 29 Emmons Drive, 08540 Princeton
IPO Datum 1994-04-04

Kennungs-Wechsel

Datum Von Zu
30.09.2009 DORB SNGX

Ticker Symbole

Name Symbol
NASDAQ SNGX

Weitere Aktien

Investoren die SOLIGENIX INC.NEW DL-,001 die halten, haben auch folgende Aktien im Depot:
AIIB 22/27 MTN
AIIB 22/27 MTN Anleihe
COCA-COLA 21/32
COCA-COLA 21/32 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025